BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31717353)

  • 1. Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides.
    Campbell BA; Ryan G; McCormack C; Tangas E; Bressel M; Twigger R; Buelens O; van der Weyden C; Prince HM
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31717353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma.
    Elsayad K; Kriz J; Moustakis C; Scobioala S; Reinartz G; Haverkamp U; Willich N; Weishaupt C; Stadler R; Sunderkötter C; Eich HT
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1077-86. PubMed ID: 26581145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.
    Hughes CF; Khot A; McCormack C; Lade S; Westerman DA; Twigger R; Buelens O; Newland K; Tam C; Dickinson M; Ryan G; Ritchie D; Wood C; Prince HM
    Blood; 2015 Jan; 125(1):71-81. PubMed ID: 25336628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
    Elsayad K; Weishaupt C; Moustakis C; Danzer MF; Müller EC; Rolf D; Stranzenbach R; Livingstone E; Booken N; Stadler R; Eich HT
    Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):164-170. PubMed ID: 36893819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.
    Papadavid E; Kapniari E; Pappa V; Nikolaou V; Iliakis T; Dalamaga M; Jonak C; Porkert S; Engelina S; Quaglino P; Ortiz-Romero PL; Vico C; Cozzio A; Dimitriou F; Guiron R; Guenova E; Hodak E; Bagot M; Scarisbrick J
    Br J Dermatol; 2021 Nov; 185(5):1035-1044. PubMed ID: 34137025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides/Sézary syndrome using Time to Next Treatment as a measure of clinical benefit: An EORTC CLTG study.
    Mitsunaga K; Bagot M; Ram-Wolff C; Guenova E; von Gugelberg C; Hodak E; Amitay-Laish I; Papadavid E; Jonak C; Porkert S; Scarisbrick J; Applewaite R; Beylot-Barry M; Nicolay J; Quaglino P; Sanches JA; Cury-Martins J; Lora-Pablos D; Ortiz P
    Br J Dermatol; 2024 Apr; ():. PubMed ID: 38596857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
    McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
    J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis.
    Kamstrup MR; Gniadecki R; Iversen L; Skov L; Petersen PM; Loft A; Specht L
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):138-43. PubMed ID: 25863761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycosis fungoides and Sézary syndrome.
    Lee H
    Blood Res; 2023 Apr; 58(S1):66-82. PubMed ID: 37105561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
    Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
    Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review.
    Liu KL; Tsai WC; Lee CH
    PLoS One; 2020; 15(1):e0228046. PubMed ID: 31978091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome.
    Hanel W; Briski R; Ross CW; Anderson TF; Kaminski MS; Hristov AC; Wilcox RA
    Am J Hematol; 2016 Dec; 91(12):E491-E495. PubMed ID: 27649045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
    Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
    Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome.
    Elsayad K; Kroeger K; Greve B; Moustakis C; Assaf C; Stadler R; Lenz G; Weishaupt C; Eich HT
    Strahlenther Onkol; 2020 Jan; 196(1):77-84. PubMed ID: 31591658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome.
    Shiratori S; Fujimoto K; Nishimura M; Hatanaka KC; Kosugi-Kanaya M; Okada K; Sugita J; Shigematsu A; Hashimoto D; Endo T; Kondo T; Abe R; Hashino S; Matsuno Y; Shimizu H; Teshima T
    Hematol Oncol; 2016 Mar; 34(1):9-16. PubMed ID: 25312300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
    Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.